SIC
RARE icon

SJS Investment Consulting’s Ultragenyx Pharmaceutical RARE Stock Holding History

SJS Investment Consulting’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Buy
381
+193
+103% +$4.79K ﹤0.01% 982
2026
Q1 		$3.94K Buy
188
+141
+300% +$3.17K ﹤0.01% 1106
2025
Q4 		$1.08K Buy
+47
New +$1.55K ﹤0.01% 1273

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

SJS Investment Consulting's RARE Position: Q2 2026 in Review

SJS Investment Consulting increased its Ultragenyx Pharmaceutical (RARE) stake by 103% in Q2 2026, buying an estimated $4.79K and bringing the position to 381 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

SJS Investment Consulting first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 117 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • SJS Investment Consulting held 381 shares of Ultragenyx Pharmaceutical worth $12.7K as of Q2 2026.
  • SJS Investment Consulting bought 193 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.79K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #982 holding.
  • SJS Investment Consulting first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 117 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.